ArticleCommunications biology2024
Hybridized quantum dot, silica, and gold nanoparticles for targeted chemo-radiotherapy in colorectal cancer theranostics.
Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Nanocarriers in psychiatry: a comprehensive review of emerging frontiers in the management of psychiatric disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Article
- EpCAM-targeted ZIF-8 nanocarriers for enhanced doxorubicin delivery in cancer therapy: a promising approach for tumor-specific drug release.Scientific reports · 2026Article
- Nanotechnology in Cancer Therapy: How Nanoparticles Are Shaping the Future of Personalized Treatment.ACS nano medicine · 2026Review
- Metallic nanoparticles in precision medicine for gastrointestinal cancers: Diagnostic and therapeutic advances.Journal of pharmaceutical analysis · 2026Review
- Nanozyme-Driven Signal Amplification in Cancer Biosensing: Innovations Toward Precision and Point-of-Care Oncology.Micromachines · 2026Review
- Boosting cancer therapy with self-assembled inorganic nanocarriers via host-guest chemistry.Materials today. Bio · 2026Review
- Nanoplatforms for Multimodal Imaging and Targeted Cancer Therapy: Recent Advances and Future Perspectives.Bioengineering (Basel, Switzerland) · 2026Review
- Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy.Journal of nanobiotechnology · 2026Review
- Quantum Dots: Catalysts for a New Era of Precision Medicine and Biomedical Innovation.Journal of fluorescence · 2026Review
- Multimodal Magnetic Nanoparticle-Quantum Dot Composites.Nanomaterials (Basel, Switzerland) · 2025Article
- Plasma-Assisted and Solvent-Free Ultra-Fast Synthesis of Gold and Gold Oxide Ultra-Small Nanoparticles and its use as Multi-Sensing Platforms.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Multifunctional nanoplatforms for tumor microenvironment remodeling: Toward precision and intelligent cancer therapy.Materials today. Bio · 2025Review
- Theranostics in the management of colorectal cancer.Discover nano · 2025Review
- Advancements in Targeted Quantum Dots Structures for Enhanced Cancer Treatment.Pharmaceutics · 2025Review
- Microwave-assisted synthesis of silica quantum dots: a novel approach for targeting PI3K/AKT signaling in breast cancer therapy.RSC advances · 2025Article
- Applications of Tailored Mesoporous Silicate Nanomaterials in Regenerative Medicine and Theranostics.International journal of molecular sciences · 2025Review
- Gold nanocomposites in colorectal cancer therapy: characterization, selective cytotoxicity, and migration inhibition.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Rational Design of Safer Inorganic Nanoparticles via Mechanistic Modeling-Informed Machine Learning.ACS nano · 2025Article
- The Role of Inorganic Nanomaterials in Overcoming Challenges in Colorectal Cancer Diagnosis and Therapy.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Multimodal nanoparticles, utilizing quantum dots (QDs), mesoporous silica nanoparticles (MSNs), and gold nanoparticles (Au NPs), offer substantial potential as a smart and targeted drug delivery system for simultaneous cancer therapy and imaging. This method entails coating magnetic GZCIS/ZnS QDs with mesoporous silica, loading epirubicin into the pores, capping with Au NPs, PEGylation, and conjugating with epithelial cell adhesion molecule (EpCAM) aptamers to actively target colorectal cancer (CRC) cells. This study showcases the hybrid QD@MSN-EPI-Au-PEG-Apt nanocarriers (size ~65 nm) with comprehensive characterizations post-synthesis. In vitro studies demonstrate the selective cytotoxicity of these targeted nanocarriers towards HT-29 cells compared to CHO cells, leading to a significant reduction in HT-29 cell survival when combined with irradiation. Targeted delivery of nanocarriers in vivo is validated by enhanced anti-tumor effects with reduced side effects following chemo-radiotherapy, along with imaging in a CRC mouse model. This approach holds promise for improved CRC theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.